SK Bioscience Co (XKRX:302440) Ending Cash Position : ₩127,026 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Ending Cash Position?

SK Bioscience Co's Ending Cash Position for the quarter that ended in Dec. 2023 was ₩127,026 Mil.

SK Bioscience Co's quarterly Ending Cash Position increased from Jun. 2023 (₩243,755 Mil) to Sep. 2023 (₩247,514 Mil) but then declined from Sep. 2023 (₩247,514 Mil) to Dec. 2023 (₩127,026 Mil).

SK Bioscience Co's annual Ending Cash Position increased from Dec. 2021 (₩98,028 Mil) to Dec. 2022 (₩225,287 Mil) but then declined from Dec. 2022 (₩225,287 Mil) to Dec. 2023 (₩127,026 Mil).

SK Bioscience Co Ending Cash Position Historical Data

The historical data trend for SK Bioscience Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Ending Cash Position Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

14,380.27

24,972.32

98,028.26

225,287.45

127,025.64

SK Bioscience Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															225,287.45	242,656.90	243,754.56	247,513.81	127,025.64

SK Bioscience Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SK Bioscience Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	225287.448	+	-98261.809
	=	127,026

SK Bioscience Co's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	247513.805	+	-120488.166
	=	127,026

SK Bioscience Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co (XKRX:302440) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines